| A Short Biotech & Genetics Industry Glossary | i |
| Introduction | 1 |
| How to Use This Book | 3 |
| Chapter 1: Major Trends Affecting the Biotech & Genetics Industry | 7 |
| 1) The State of the Biotechnology Industry Today | 7 |
| 2) A Short History of Biotechnology | 11 |
| 3) Ethanol Production Soared, But a Market Glut May Slow Expansion | 12 |
| 4) New Money Pours into Biotech Firms/Mergers and Acquisitions Surge Ahead | 15 |
| 5) Major Drug Companies Bet on Partnerships With Smaller Biotech Research Firms | 16 |
| 6) From India to Singapore to Australia, Nations Compete Fiercely in Biotech Development | 16 |
| 7) Medical Trials Conducted Abroad Spark Concerns | 18 |
| 8) Gene Therapies and Patients' Genetic Profiles Promise a Personalized Approach to Medicine | 18 |
| 9) Breakthrough Drugs for Cancer Treatment - Many More Will Follow | 20 |
| 10) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues | 21 |
| 11) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age | 23 |
| 12) Biogenerics (Follow-on Biologics) are in Limbo in the U.S. | 24 |
| 13) Breakthrough Drug Delivery Systems Evolve | 25 |
| 14) Stem Cells - Multiple Sources Stem from New Technologies | 26 |
| 15) U.S. Government Reverses Ban on Funding for New Stem Cell Research | 28 |
| 16) Stem Cells - Therapeutic Cloning Techniques Advance | 29 |
| 17) Stem Cells - A New Era of Regenerative Medicine Takes Shape | 30 |
| 18) Nanotechnology Converges with Biotech | 31 |
| 19) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise | 32 |
| 20) Focus on Vaccines | 35 |
| 21) Ethical Issues Abound | 36 |
| 22) Technology Discussion - Genomics | 36 |
| 23) Technology Discussion - Proteomics | 37 |
| 24) Technology Discussion - Microarrays | 37 |
| 25) Technology Discussion - DNA Chips | 37 |
| 26) Technology Discussion - SNPs ( - Snips - ) | 38 |
| 27) Technology Discussion - Combinatorial Chemistry | 38 |
| 28) Technology Discussion - Synthetic Biology | 38 |
| 29) Technology Discussion - Recombinant DNA | 39 |
| 30) Technology Discussion - Polymerase Chain Reaction (PCR) | 39 |
| Chapter 2: Biotech & Genetics Industry Statistics | 41 |
| Biotech Industry Overview | 42 |
| Global Biotechnology at a Glance: 2008 | 43 |
| Growth in Global Biotechnology: 2007-2008 | 44 |
| U.S. Biotechnology at a Glance: 2007-2008 | 45 |
| Biotechnology Financing, U.S., Europe & Canada: 2007-2008 | 46 |
| Quarterly Breakdown of Biotechnology Financings, U.S. & Canada: 2008 | 47 |
| Ernst & Young Survival Index, U.S. & Canadian Biotechnology Companies: 2007-2008 | 48 |
| The U.S. Drug Discovery & Approval Process | 49 |
| U.S. FDA Approval Times for New Drugs: 1993-2008 | 50 |
| U.S. FDA Approval Times for New Molecular Entities (NMEs): 1993-2008 | 51 |
| U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME)Approvals: 1993-2008 | 52 |
| Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2008 | 53 |
| Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2007-2009 | 54 |
| National Health Expenditure Amounts by Type of Expenditure, U.S.: Selected Calendar Years, 2003-2018 | 55 |
| U.S. Exports & Imports of Pharmaceutical Products: 2003-1st Quarter 2009 | 56 |
| U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: Selected Calendar Years, 2003-2018 | 57 |
| Prescription Drug Expenditures, U.S.: 1965-2018 | 58 |
| Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2008 | 60 |
| Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Year 2009-2010 | 61 |
| Global Area of Biotech Crops by Country: 2008 | 62 |
| R&D as a Percentage of U.S. Biopharmaceutical Sales, PhRMA Member Companies: 1970-2008 | 63 |
| Biologics & Biotechnology R&D, PhRMA Member Companies: 2007 | 64 |
| Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1970-2008 | 65 |
| Sales By Geographic Area, PhRMA Member Companies: 2007 | 66 |
| Domestic Biopharmaceutical R&D Breakdown, PhRMA Member Companies: 2007 | 67 |
| R&D by Global Geographic Area, PhRMA Member Companies: 2007 | 68 |
| Domestic Biopharmaceutical R&D Scientific, Professional & Technical Personnel by Function, PhRMA Member Companies: 2007 | 69 |
| Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1970-2008 | 70 |
| Chapter 3: Important Biotech & Genetics Industry Contacts | 71 |
| (Addresses, Phone Numbers and Internet Sites) | |
| Chapter 4: THE BIOTECH 400: | |
| Who They Are and How They Were Chosen | 109 |
| Industry List, With Codes | 110 |
| Index of Rankings Within Industry Groups | 111 |
| Alphabetical Index | 120 |
| Index of U.S. Headquarters Location by State | 123 |
| Index of Non-U.S. Headquarters Location by Country | 127 |
| Index by Regions of the U.S. Where the Firms Have Locations | 128 |
| Index by Firms with International Operations | 134 |
| Individual Profiles on Each of THE BIOTECH 400 | 137 |
| Additional Indexes | |
| Index of Hot Spots for Advancement for Women/Minorities | 518 |
| Index by Subsidiaries, Brand Names and Selected Affiliations | 520 |